Oncology Office Solid Tumor Requisition

FAX: 239.690.4237
☐ *Include face sheet or insurance info.*
☐ *Include pathology report*
Phone: 866.776.5907
neogenomics.com

Client Information

Required Information

Account #: _____ **Account Name:** _____
Street Address: _____
_____
City, ST, ZIP: _____
Phone: _____ **Fax:** _____

Requisition Completed by: _____ Date: _____
Ordering Physician (please print: Last, First): _____ NPI #: _____
Treating Physician (please print: Last, First): _____ NPI #: _____

The undersigned certifies that he/she is licensed to order the test(s) listed below and that such test(s) are medically necessary for the care/treatment of this patient.

Authorized Signature: _____ Date: _____

Billing Information

Required: Please include face sheet and front/back of patient's insurance card.

Patient Status (Must Choose 1):
☐ Hospital Patient (in)
☐ Hospital Patient (out)
☐ Non-Hospital Patient

Bill to: ☐ Client Bill ☐ Insurance
☐ Medicare ☐ Medicaid ☐ Patient/Self-Pay
☐ Bill charges to other Hospital/Facility:
_____

Prior Authorization #_____ See the NeoGenomics.com Billing section for more info.

Clinical Information

Required: Please attach patient's pathology report (required), clinical history, and other applicable report(s).
ICD-10 (Diagnosis) Code/Narrative (Required): _____

Reason for Referral: _____
☐ New Diagnosis ☐ Relapse ☐ In Remission ☐ Monitoring
Staging: ☐ 0 ☐ I ☐ II ☐ III ☐ IIIA ☐ IIIB ☐ IV Note: _____

Patient Information

Last Name: _____ ☐ **Male** ☐ **Female**
First Name: _____ **M.I.** _____ Other Pt ID/Acct #: _____
Date of Birth: mm _____ / dd _____ / yyyy _____ Medical Record #: _____
Client represents it has obtained informed consent from patient to perform the services described herein.

Specimen Retrieval

Client Services will request specimen from Pathology site.
Location of Specimen: _____
Address: _____
City: _____ State: _____ Zip Code: _____
Phone: _____ Fax: _____
Note: _____
Body Site: _____
☐ Primary ☐ Metastasis – If Metastasis, list Primary: _____

Specimen Information

Specimen ID: _____ **Block ID:** _____
Fixative/Preservative: _____ **Retrieved Date:** mm _____ / dd _____ / yyyy _____
Hospital Discharge Date: mm _____ / dd _____ / yyyy _____
Collection Date: mm _____ / dd _____ / yyyy _____ **Collection Time:** _____ ☐ AM ☐ PM

☐ Slides # _____ Unstained _____ Stained _____ ☐ H&E _____
☐ Paraffin Block(s) #: _____ ☐ **Choose best block** (global testing only)
☐ Peripheral Blood #: _____ ☐ **Perform tests on all blocks**

Breast Marker & GI HER2 Fixation (CAP/ASCO Requirement for Breast and Non-Breast)
Cold ischemic time ≤ 1 hour: ☐ Yes ☐ No ☐ Unknown
10% neutral buffered formalin: ☐ Yes ☐ No ☐ Unknown
HER2/ER/PgR Fixation duration 6 to 72 hours: ☐ Yes ☐ No ☐ Unknown

Consultation

A NeoGenomics pathologist will select medically necessary tests (with any exception noted below by the client) to provide comprehensive analysis and professional interpretation for the materials submitted.

☐ **Surgical Pathology Consult** **Differential Diagnosis:**
☐ Add NeoTYPE® Profile if indicated _____

NeoTYPE® Cancer Profiles

Broad- Reach Profiles
☐ Discovery Profile (300+ genes, TMB, MSI, FISH, IHC)^
☐ Precision Profile (70+ genes, TMB, MSI,IHC)^

Selected Tumor-Specific Profiles
☐ Esophageal Profile
☐ GIST & Soft Tissue Profile
☐ HRD+ Profile
☐ Liver/ Biliary Profile
☐ Other Solid Tumor Profile
☐ Pancreas Tumor Profile

Liquid Biopsy
☐ InVisionFirst®-Lung
☐ NeoLAB® Solid Tumor Liquid Biopsy
PIK3CA Mutation CDx-Plasma: Call Client Services.

Unknown or Uncertain Tumor Type
☐ **CancerTYPE ID®† with reflex to NeoTYPE Cancer Profile** based on CancerTYPE ID result
Tumor classification followed by targeted biomarkers

Ob/Gyn
☐ NeoTYPE Cervical Tumor Profile
☐ NeoTYPE Endometrial Tumor Profile
☐ NeoTYPE Ovarian Tumor Profile
☐ NeoTYPE HRD+ Profile
☐ BRCA1/2 Mutation Analysis for Tumors
☐ PD-L1 22C3 FDA (KEYTRUDA®) for Cervical
☐ NTRK & RET NGS Fusion Profile

Sarcoma
☐ NeoTYPE Liposarcoma Fusion Profile
☐ NGS Comprehensive Fusion Profile
☐ NGS Ewing Fusion Profile
☐ NGS Non-Ewing Fusion Profile
☐ NGS Rhabdomyosarcoma Fusion Profile
☐ DDIT3 (CHOP) (FISH) ☐ EWSR1 (FISH)
☐ MDM2 (FISH) ☐ PDGFB (FISH)
☐ SS18 (SYT) (FISH)

Breast Cancer
☐* ER/PgR/HER2**
☐* ER/PgR/HER2**/Ki67
☐* ER/PgR/HER2**/Ki67/p53
☐ Individual Stains:
☐ ER ☐ PgR ☐ HER2** ☐ Ki67 ☐ p53
☐* Reflex to global PD-L1 SP142 TNBC if global ER/PgR/ER2 panel is negative
** For global HER2 IHC with result 2+, NeoGenomics will add global HER2 FISH unless marked here: ☐Do not reflex 2+.
☐ HER2 (FISH)
☐Reflex to HER2 IHC if HER2 FISH result is Group 2, 3, or 4 (see back)
• For global HER2 FISH: Send path report. If HER2 IHC has been interpreted elsewhere: Send IHC report and also send HER2 IHC slide if result is 2+.
☐ NeoTYPE Breast Tumor Profile
☐ NeoTYPE HRD+ Profile
☐ BRCA1/2 Mutation Analysis for Tumors
☐ PD-L1 SP142 FDA (TECENTRIQ®) for TNBC Breast
PIK3CA Mutation CDx, Prosigna®, Breast Cancer Index® (BCI): separate requisitions required, see website.

Colorectal Cancer
☐ NeoTYPE Colorectal Tumor Profile
☐ NeoTYPE GI Predictive
☐ MMR IHC
☐ Reflex to BRAF if MLH1 IHC is not expressed
☐ Reflex MMR to _____ if MMR _____
☐ Microsatellite Instability (MSI) Non-tumor tissue is required.
☐ Reflex to MMR if MSI is high
☐ Reflex to BRAF if MLH1 IHC is not expressed
☐ NTRK & RET NGS Fusion Profile
☐ RAS/RAF Panel (BRAF, HRAS, KRAS, NRAS)
Test4TRK Sponsored Testing Program: separate requisition required, see website.

Brain Cancer
☐ NeoTYPE Brain Tumor Profile
☐ 1p/19q Deletion (FISH)
☐ IDH1/IDH2 (Mol.)
☐ MGMT Methylation (Mol.)
☐ NTRK NGS Fusion Profile

Melanoma
☐ NeoTYPE Melanoma Profile
☐ NeoSITE™ Melanoma FISH Panel
☐ BRAF (Molecular)
☐ KIT (Molecular)
☐ NRAS (Molecular)
☐ THxID® BRAF (Molecular)

Head and Neck Cancer
☐ NeoTYPE Head & Neck Tumor Profile
☐ PD-L1 22C3 FDA (KEYTRUDA®) for HNSCC

Bladder Cancer
☐ Bladder Cancer FISH (urine only)
☐ FGFR CDx Molecular Analysis
☐ PD-L1 22C3 FDA (KEYTRUDA®)
☐ PD-L1 SP142 FDA (TECENTRIQ®)
☐ PD-L1 28-8 (OPDIVO®)
☐ PD-L1 SP263 FDA (IMFINZI™)

Prostate Cancer
☐ NeoTYPE HRD+ Profile
☐ Androgen Receptor (Molecular)
☐ PTEN (FISH)

Thyroid Cancer
☐ NeoTYPE Thyroid Tumor Profile
☐ NTRK & RET NGS Fusion Profile
Thyroid & Test4TRK Sponsored Testing Programs: separate requisitions required, see website.

Other/Pan-Cancer Testing
☐ BRAF (Mol.)
☐ FGFR2 Rearr. FISH
☐ HPV DNA (Mol.)
☐ KIT (Mol.)
☐ KRAS (Exons 2-4)
☐ MLH1 Promoter Methylation (Mol.)
☐ MYC FISH for Angiosarcoma
☐ NRAS (Exon 2-4)
☐ NTRK NGS Fusion Profile
☐ NTRK 1,2,3 FISH Panel
☐ Pan-TRK (IHC)
☐ Reflex to NTRK NGS Fusion
☐ Reflex to NTRK 1,2,3 FISH
☐ Other Molecular _____
☐ Other FISH _____
☐ Other IHC _____

Lung Cancer
☐ NeoTYPE Lung Tumor Profile^
☐ Lung NGS Fusion Profile (ALK, NTRK 1-3, RET, ROS1)
☐ NTRK NGS Fusion Profile (NTRK 1-3)
☐ Oncomine Dx Target Test (Mol)
☐ PD-L1 22C3 FDA (KEYTRUDA®)
☐ PD-L1 28-8 FDA (OPDIVO ®+YERVOY®)
☐ PD-L1 SP142 FDA (TECENTRIQ®)
☐ EGFR (Mol.), ALK (FISH), ROS1 (FISH), BRAF (Mol.) Results will be reported separately.
☐ MET (FISH), MET EXON 14 Deletion (Mol.) Results will be reported separately.
☐ ALK (FISH)
☐ EGFR (Mol.)
☐ RET (FISH)
☐ ROS1 (FISH)
☐ KRAS (includes G12C mutation)
☐ InVisionFirst®-Lung Liquid Biopsy

GI Cancer
☐ NeoTYPE Gastric Tumor Profile
☐ NeoTYPE GI Predictive
☐ HER2 (IHC)*
• Reflex to HER2 (FISH) if HER2 (IHC) is:
☐ 0 ☐ 1+ ☐ 3+
*For global HER2 IHC with result 2+, NeoGenomics will add global HER2 FISH unless marked here:
☐ Do not reflex 2+
☐ HER2 (FISH)
• Reflex to HER2 (IHC) if HER2 (FISH) is:
☐ positive ☐ negative ☐ indeterminate
☐ KIT (Molecular)
☐ NTRK & RET NGS Fusion Profile
☐ PD-L1 22C3 FDA (KEYTRUDA) for ESCC (Esophageal)
☐ PD-L1 22C3 FDA (KEYTRUDA) for Gastric/GEA
☐ PDGFRa (Molecular)

For our complete test menu, please visit **neogenomics.com**. †To order CancerTYPE ID as a stand-alone test, visit www.cancertypeid.com ^EGFR PCR will be added to lung specimens submitted for these Profiles if insufficient for NGS. Rev. 062620

Specimen Requirements

Liquid biopsy tests InVisionFirst®-Lung and NeoLAB® Solid Tumor Liquid Biopsy: Do not refrigerate. Special collection tubes and shipping requirements apply. Please contact Client Services for kits and see instructions provided in kit.
All other tests: Refrigerate specimen if not shipping immediately and use cool pack during transport.
Please call Client Services Team with any questions regarding specimen requirements or shipping instructions at 866.776.5907 option 1. Please refer to the website for specific details on each specimen.

Additional Billing Information

Any organization referring specimens for testing services pursuant to this Requisition Form ("Client") expressly agrees to the following terms and conditions.

1. **Binding Service Order.** This Requisition Form is a legally binding order for the services ordered hereunder ("Services") and Client agrees that it is financially responsible for all tests billable to Client hereunder.

2. **Third Party Billing by NeoGenomics and Right to Bill Client.** Client agrees to accurately indicate on the front of the Requisition Form that either Client should be billed (e.g., Client receives reimbursement pursuant to a non-fee-for-service basis, including, but not limited to, a capitated, diagnostic related group ("DRG"), per diem, all-inclusive, or other such bundled or consolidated billing arrangement) or NeoGenomics should bill the applicable federal, state or commercial health insurer or other third party payer (collectively, "Payers") for all Services ordered pursuant to this Requisition Form. For all such Services billable to Payers, Client agrees to provide all billing information necessary for NeoGenomics to bill such payer. In the event NeoGenomics: (i) does not receive the billing information required for it to bill any Payers within ten days of the date that any Services are reported by NeoGenomics; (ii) the Services were performed for patients who have no Payer coverage arrangements; or (iii) the Payer identified by Client denies financial responsibility for the Services and indicates that Client is financially responsible, NeoGenomics shall have the right to bill such Services to Client.

Test Descriptions

Please see complete test descriptions and all available tests at our website, www.neogenomics.com.

Test Notations

Specimen Usage

NeoGenomics makes every effort to preserve and not exhaust tissue, but in small and thin specimens, there is a possibility of exhausting the specimen in order to ensure adequate material and reliable results.

Breast HER2, ER, PgR (IHC) and Breast HER2 (FISH)

Breast specimens undergoing any of these tests should be invasive breast cancer or the invasive component of the breast cancer fixed in 10% neutral buffered formalin for at least 6 hours and no longer than 72 hours.

For global breast HER2 FISH cases, NeoGenomics will (if requested) reflex FISH to HER2 IHC if FISH results are consistent with CAP/ASCO 2018 result Groups 2, 3, or 4 for dual-probe ISH assays.

- Group 2: HER2/CEP17 ratio ≥ 2.0 and average HER2 copy number < 4.0 signals/cell
- Group 3: HER2/CEP17 ratio < 2.0 and average HER2 copy number ≥ 6.0 signals/cell
- Group 4: HER2/CEP17 ratio < 2.0 and average HER2 copy number ≥ 4.0 and < 6.0 signals/cell

If ordering global HER2 FISH after HER2 IHC was already interpreted outside NeoGenomics, please send the HER2 IHC result and the path report. If that IHC result was 2+, please submit the HER2-stained IHC slide to NeoGenomics with the FISH order so that we may correlate our analysis. This includes stain-only cases that were not scanned by NeoGenomics. If outside HER2 IHC results were other than 2+, we do not request the IHC slide but still request the HER2 IHC report.

CancerTYPE ID® with reflex to NeoTYPE® Cancer Profile

The specific NeoTYPE Cancer Profile added is determined by the CancerTYPE ID result. See www.neogenomics.com for test details.

CancerTYPE ID will be performed, reported and billed separately by Biotheranostics, Inc. For comprehensive details about CancerTYPE ID including test description, intended use, and limitations, visit www.cancertypeid.com.

InVisionFirst®-Lung

InVisionFirst®-Lung liquid biopsy testing is performed by Inivata. See www.neogenomics.com for test details.

Rev. 062620